A Lupron shot is a brand-name injection of leuprolide acetate, a synthetic hormone that ultimately shuts down the body’s production of sex hormones like testosterone and estrogen. Doctors prescribe it across a surprisingly wide range of conditions, from advanced prostate cancer and endometriosis to early puberty in children and even as part of fertility treatment protocols. Despite the drug being in clinical use for decades, many patients receive a Lupron prescription without fully understanding what the shot does once it enters the body, why certain side effects happen, or how long recovery takes after stopping.
How the Lupron Shot Works
Leuprolide acetate belongs to a class of drugs called GnRH agonists. Your brain naturally produces a small signaling hormone called gonadotropin-releasing hormone (GnRH) in pulses, which tells the pituitary gland to release the hormones that drive testosterone and estrogen production. Leuprolide is a modified version of that natural hormone, engineered to resist breakdown in the body and stick around much longer than the real thing.1PubMed Central. Gonadotropin releasing hormone agonists: Expanding vistas When you flood the system with a constant GnRH signal rather than the normal pulsing pattern, something counterintuitive happens: the pituitary gland initially revs up, but within a few weeks it essentially burns out its GnRH receptors and stops responding. The result is a dramatic drop in sex hormones to very low levels, sometimes called “medical castration” in the prostate cancer context.
This two-phase response is crucial to understand because it explains the most confusing aspect of the drug for many patients. In the first one to three weeks after the initial injection, testosterone or estrogen levels actually spike before they crash. In men, testosterone can rise by roughly 40 to 100 percent in the first two to three days, returning to baseline by about a week and then falling to very low levels within two to three weeks.2PubMed. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth This initial surge is called “flare,” and for prostate cancer patients it can temporarily worsen symptoms. Doctors often prescribe a short course of an anti-androgen drug alongside the first Lupron injection to block flare effects.3PubMed Central. Flare Associated with LHRH-Agonist Therapy
Lupron for Prostate Cancer
The most common use of the Lupron shot in adults is to suppress testosterone in men with prostate cancer. Since prostate cancer cells typically depend on testosterone to grow, driving testosterone down to castrate levels (generally below 50 ng/dL) slows the disease. In clinical trials of a six-month depot formulation, over 93 percent of men achieved sustained testosterone suppression through 48 weeks. By week four, mean testosterone dropped below castrate levels and stayed there for the full duration of each injection cycle.4PubMed Central. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer A newer three-month formulation showed similarly strong results, with about 97 percent of patients maintaining castrate levels throughout treatment.5PubMed. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer
These numbers matter because even small “escapes” where testosterone creeps back up can raise concerns about disease control. In the six-month depot study, nine patients had brief testosterone escapes, but none of those escapes were accompanied by a rise in PSA, the protein used to track prostate cancer activity.6PubMed Central. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer That finding, along with data on the initial testosterone flare itself, has eased some long-standing anxieties among oncologists. Of six studies that tracked PSA during the flare window, five found no meaningful PSA rise even in men with advanced disease and very high baseline PSA levels.7PubMed. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth
Endometriosis and Uterine Fibroids
Lupron is also prescribed to women with endometriosis and uterine fibroids, conditions that are driven or worsened by estrogen. By suppressing estrogen to postmenopausal levels, the drug can shrink endometrial implants and fibroid tissue, providing relief from chronic pelvic pain, heavy bleeding, and related symptoms. This use is typically limited to six months at a time, and a significant concern is bone density loss during treatment. In a year-long study, women who received leuprolide alone lost an average of about six percent of their bone density.8PubMed. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study
That bone loss is the main reason doctors frequently prescribe what is called “add-back therapy” alongside Lupron. Add-back involves giving back small amounts of estrogen and/or a progestin, enough to protect bones and ease menopausal symptoms like hot flashes without reactivating the endometriosis itself. A consensus review found that during 12 months of GnRH agonist therapy, bone density loss can be effectively eliminated with certain progestin-based add-back regimens.9Fertility and Sterility. Consensus statement on the role of add-back therapy for patients with endometriosis administered GnRH agonists In the same year-long study that showed six percent bone loss with Lupron alone, all three add-back groups had their bone density preserved.10PubMed. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study If you are prescribed Lupron for endometriosis or fibroids and your doctor does not mention add-back, it is worth asking about.
Treating Central Precocious Puberty in Children
Central precocious puberty (CPP) occurs when puberty begins unusually early, typically before age eight in girls or age nine in boys. Left untreated, it can cause children to stop growing sooner and reach a shorter adult height than they otherwise would, along with the psychosocial challenges of developing years ahead of peers. Lupron has been a standard treatment for CPP for decades, working by the same mechanism: it pauses the hormonal signals driving premature puberty until the child reaches an appropriate age.
The height data are encouraging. In a prospective study of girls treated with a one-month leuprolide depot, the mean adult height was about 162.5 cm, representing an average gain of roughly four centimeters over the predicted adult height at the start of treatment. These children essentially reached the mean height of the normal population by adulthood.11PubMed Central. Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study Another study reported predicted adult height increases of about 5.5 cm over baseline after 18 months of treatment, alongside clear deceleration of bone age advancement.12The Journal of Pediatrics. Two-year results of treatment with depot leuprolide acetate for central precocious puberty Longer-term follow-up studies comparing treated children to historical untreated groups found that treated girls and boys both ended up significantly closer to their genetic target height than untreated counterparts, with the benefit being clearest in the youngest children.13The Journal of Clinical Endocrinology & Metabolism. Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years
Bone health during treatment does warrant monitoring. One study of children on leuprolide for CPP found that over half of treated patients showed signs of reduced bone density, and vitamin D levels were lower in the treatment group compared to controls.14PubMed Central. An Examination of the Effects of Leuprolide Acetate Used in the Treatment of Central Precocious Puberty on Bone Mineral Density and 25-Hydroxy Vitamin D Pediatric endocrinologists typically keep an eye on bone markers and supplement vitamin D and calcium when needed.
Lupron in Fertility Treatment and IVF
It can seem paradoxical that a drug designed to suppress hormones would play a role in fertility treatment, but GnRH agonists including leuprolide have specific uses during in vitro fertilization (IVF) cycles. One application involves using a GnRH agonist as the “trigger shot” to induce final egg maturation before retrieval, instead of the traditional hCG trigger. This approach has gained traction because it substantially lowers the risk of ovarian hyperstimulation syndrome (OHSS), a potentially dangerous complication of IVF. In egg donor cycles using a GnRH agonist trigger, donors reported milder OHSS symptoms compared to cycles using hCG triggers.15PubMed Central. Egg donor self-reports of ovarian hyperstimulation syndrome: severity by trigger type, oocytes retrieved, and prior history Research on GnRH agonist triggers has shown they can essentially abolish the risk of severe OHSS, though they may require additional hormonal support afterward to maintain the uterine lining.16PubMed Central. The Trigger in IVF Cycles: Molecular Pathways and Clinical Implications
In another study focused specifically on women with polycystic ovary syndrome or a history of high ovarian response, using a GnRH agonist trigger resulted in zero cases of OHSS in the treatment group, compared to one case of moderate OHSS in the control group.17Reproductive BioMedicine Online. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS For women at high risk of this complication, a GnRH agonist trigger has become a genuinely valuable safety tool.
Puberty Suppression in Gender-Diverse Youth
Leuprolide is also used to pause puberty in transgender and gender-diverse adolescents, providing time for psychological assessment and informed decision-making before irreversible pubertal changes occur. A comparison of two leuprolide formulations (subcutaneous Eligard and intramuscular Lupron) in gender-diverse youth found both effective at suppressing clinical puberty progression, including in patients who were also receiving gender-affirming hormones.18PubMed. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron One cardiac safety concern that has been raised with GnRH agonist use is the possibility of QTc prolongation, an electrical change in the heart that can sometimes signal arrhythmia risk. A study examining this directly in gender-diverse youth on leuprolide found no clinically significant QTc prolongation.19PubMed Central. Leuprolide Acetate and QTc Interval in Gender-Diverse Youth
Common Side Effects
Because Lupron works by suppressing sex hormones, its side effects largely mirror what you would expect from hormone depletion. An analysis of FDA adverse event reports for leuprolide and a related drug found that the most frequently reported side effects included hot flashes, changes in sexual function, reduced bone density, headaches, and mood fluctuations.20PubMed Central. Evaluation of adverse event profiles for leuprolide and goserelin: Insights from the FDA adverse event reporting system following STROBE guidelines Hot flashes tend to be especially common early in treatment, when hormone levels are dropping rapidly.
Bone density loss is one of the more serious longer-term concerns. In men on androgen deprivation therapy for prostate cancer, GnRH agonists increase bone turnover and decrease bone mineral density, raising the risk of fractures over time.21PubMed Central. Treatment-related osteoporosis in men with prostate cancer The good news is that bone density usually recovers after the drug is stopped, at least for shorter courses. However, after long-term use, that recovery may not be complete.22Fertility and Sterility. Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture
Mood and cognitive effects are harder to pin down. A controlled study in healthy men who were given Lupron to temporarily suppress their hormones found that, on average, most measured mood symptoms did not change significantly between the normal-hormone, suppressed-hormone, and testosterone-replacement conditions. But three men out of the group did experience clinically meaningful mood symptoms during the low-hormone phase, and men with high baseline sexual functioning experienced the steepest declines in that area.23Archives of General Psychiatry. The Effects of Pharmacologically Induced Hypogonadism on Mood in Healthy Men In other words, most people tolerate the hormonal suppression without major psychological disturbance, but a subset are more vulnerable, and there is no reliable way to predict who that will be ahead of time.
Metabolic and Cardiovascular Risks With Long-Term Use
For men on long-term androgen deprivation therapy (typically a year or more), the metabolic picture gets more complicated. Studies have found a higher prevalence of diabetes and metabolic syndrome in men on prolonged ADT compared to controls, along with higher cardiovascular mortality.24PubMed. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth Body composition changes, unfavorable cholesterol shifts, and insulin resistance emerge within months of starting medical ADT, and the risk of serious cardiovascular events can become evident on a similarly short timeline.25PubMed. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer These metabolic changes can persist even after the therapy ends. For men who will be on Lupron for years, monitoring blood sugar, lipids, and cardiovascular risk factors is an important part of their care.
Available Formulations
One of the practical features of Lupron is the range of injection schedules available. Formulations exist as one-month, three-month, four-month, and six-month depots. The longer-acting versions reduce the number of clinic visits and injections, which can meaningfully improve compliance and convenience.26PubMed Central. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort Across formulations, injection site pain is the most commonly reported immediate adverse event.27F&S Reports. Clinical development of the GnRH agonist leuprolide acetate depot – Section: Clinical development of lupron depot-ped for the treatment of cpp in children
For children being treated for CPP, both the monthly and three-monthly formulations appear effective. A retrospective comparison of 143 girls found that the three-monthly regimen actually produced more significant hormonal suppression, and the two groups reached comparable predicted adult heights by the end of treatment.28PubMed Central. Effectiveness of leuprolide acetate administered monthly compared to three-monthly in the treatment of central precocious puberty: evaluation at the end of treatment For families weighing the trade-offs, fewer trips to the doctor for injections is often a significant quality-of-life factor, especially for a young child who dreads needles.
What Happens When You Stop
A common question patients ask is how quickly their body returns to normal after stopping Lupron. The answer depends on how long they were on the drug. In men who had been on prolonged LHRH agonist therapy for prostate cancer, recovery of the hormonal axis was variable, and castrate-level testosterone could persist for up to a year after the last injection.29PubMed. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer A study specifically tracking testosterone recovery in men who had been on long-term treatment found that all patients eventually showed some recovery, but the first detectable testosterone took an average of about 13 months, and it took an average of roughly 17 to 18 months for testosterone to reach normal levels.30PubMed. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer For shorter treatment courses, such as the six-month endometriosis regimen or puberty suppression in children, recovery typically happens much faster, though exact timelines vary.
This delayed recovery matters for planning. If you are stopping Lupron because your cancer treatment is moving to a different approach, your oncologist needs to account for the fact that you may remain in a low-testosterone state for many months. If you are a woman who was on Lupron for endometriosis and is now trying to conceive, your cycle may take some time to resume. And for adolescents who discontinue puberty suppression, puberty generally picks back up where it left off, though the timeline varies by individual.
Newer Alternatives and How They Compare
Lupron has been the dominant GnRH-based therapy for decades, but a newer oral alternative called relugolix (brand name Orgovyx) has emerged as a competitor in the prostate cancer space. Relugolix works differently: rather than overstimulating the pituitary to shut it down, it directly blocks the GnRH receptor from the start, meaning there is no initial testosterone flare at all. In the HERO phase 3 trial, relugolix achieved sustained castrate testosterone levels in about 97 percent of men through 48 weeks, compared to roughly 89 percent for leuprolide.31PubMed. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
The speed difference was dramatic: by day four, 56 percent of men on relugolix had already reached castrate testosterone levels versus zero percent on leuprolide, and by day 15 the split was 99 percent versus 12 percent.32International Journal of Radiation Oncology, Biology, Physics. Androgen Deprivation Therapy With Relugolix or Leuprolide in Patients With Prostate Cancer Requiring Radiation Therapy: An Analysis of the HERO Phase 3 Trial Perhaps more meaningfully, testosterone recovery after stopping was far faster with relugolix: mean testosterone 90 days after discontinuation was about 288 ng/dL in the relugolix group compared to about 59 ng/dL in the leuprolide group. The relugolix group also showed roughly half the rate of major cardiovascular events.33PubMed. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer These advantages are real, though relugolix does require taking a daily pill rather than getting an injection every few months, which introduces its own compliance challenges. Missing doses of an oral GnRH antagonist can allow testosterone to rebound quickly, which is the flip side of the faster recovery that looks appealing at the end of treatment.
Cost and Access Considerations
Lupron is not cheap, and cost is a practical factor for many patients. A health economic analysis comparing medical hormonal therapy (including GnRH agonists) with surgical castration for metastatic prostate cancer found that medical therapy cost roughly $11,600 more over 30 months. All surveyed patients said avoiding surgery was worth the extra expense, but when asked whether they would pay that amount out of pocket, about half said they could not afford it.34Journal of Urology. The Cost Value of Medical Versus Surgical Hormonal Therapy for Metastatic Prostate Cancer Insurance coverage varies widely depending on the indication. For pediatric CPP, a comparison of leuprolide and histrelin (an implantable GnRH agonist) across commercial and Medicaid populations found similar overall healthcare costs between the two treatments.35PubMed. Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations If cost is a concern, it is worth discussing the full range of formulation options and alternative agents with your doctor, since there may be a less expensive route to the same clinical result.